Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Intangibles: 2021-2024

Historic Intangibles for Collegium Pharmaceutical (COLL) over the last 4 years, with Dec 2024 value amounting to $891.4 million.

  • Collegium Pharmaceutical's Intangibles fell 23.43% to $725.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $725.0 million, marking a year-over-year decrease of 23.43%. This contributed to the annual value of $891.4 million for FY2024, which is 111.38% up from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Intangibles is $891.4 million, which was up 111.38% from $421.7 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Intangibles high stood at $891.4 million for FY2024, and its period low was $421.7 million during FY2023.
  • Moreover, its 3-year median value for Intangibles was $567.5 million (2022), whereas its average is $626.9 million.
  • Its Intangibles has fluctuated over the past 5 years, first declined by 25.69% in 2023, then soared by 111.38% in 2024.
  • Collegium Pharmaceutical's Intangibles (Yearly) stood at $521.2 million in 2021, then increased by 8.88% to $567.5 million in 2022, then declined by 25.69% to $421.7 million in 2023, then soared by 111.38% to $891.4 million in 2024.